2021-10-29 13:49:00
Eevia Health Plc received new sales orders for organic pine bark extract
Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from a leading organic supplement brand for supply of the Fenoprolic® 70 Organic (organic pine bark extract). The sales value of this start order is c.65,000 EUR, but the customer has a strong record on new product launches, and it is therefore expected to create repeat sales of this product going forward.
Eevia exhibited at the trade show "Supply Side West" in Las Vegas this week (25-28.10.21). In connection to this exhibit Eevia received a start order for EUR 65,000 worth of Fenoprolic® 70 Organic (pine bark extract), from one of the leading organic brands in the US. The customer is a leader in natural, organic supplements, functional food, and health care with over 100 products under one strong company brand. The customer launches the product in multiple sales channels in North America.
Fenoprolic® 70 Organic is an extract from pine bark, which is standardized with 70% oligomeric proanthocyanidins (or often referred to as "OPCs" in the industry). OPCs from pine bark are known to support healthy inflammatory response, maintain a healthy blood pressure and protects against oxidative damage in blood vessels. Eevia stands out by offering an organic certified product and with ten times stricter purity standards for pollutants than key competitors.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc Kim Nurmi-Aro, CFO, Eevia Health Plc
Email: [email protected] [email protected]
Telephone: +358 400 22 5967 +358 504 44 0717
About Eevia
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are mostly wild harvested and key raw materials are harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B to dietary supplements and food brands globally, who utilize the products as ingredients in their consumer product formulas.
Eevia Health is fast-growing Finnish manufacturer of 100% organically certified plant extracts. Most of its raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36% anthocyanins) and pine bark extracts (70% oligomeric proanthocyanidins), are organically certified.
Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw material harvest areas. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia is listed at Spotlight Stock Market with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Nerladdningsbara filer
Eevia Health Plc receives multiple smaller sales orders in total EUR 30k
2023-01-31 15:10
Eevia Health ("Eevia" or "The Company") received several smaller sales orders for multiple products from multiple Finnish and European customers for a combined value of just over EUR 30k.
Eevia Health Plc receives a USD 200K sales order for Feno-Sambucus™ 7 Organic
2023-01-18 12:20
Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.
FLAGGING OF A TRANSACTION BETWEEN PMDRS IN EEVIA HEALTH PLC
2023-01-16 13:51
Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.
CORRECTION Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product
2023-01-13 13:48
Due to a misjudgement, the MAR label was added to the original press release. The press release did not contain any insider information or other reason for the MAR label. This press release is a correction without the MAR label.
Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.
Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product
2023-01-13 08:30
Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.
Last day of trading in paid subscription shares (Swedish: BTA) in Eevia Health Plc
2022-12-19 14:35
Eevia Health Plc's ("Eevia" or "the Company") preferential rights issue has now been registered with the Finnish Trade Register. Paid Subscription Shares (Swedish: BTA) will thus be replaced by ordinary shares. The last day for trading with BTA on Spotlight Stock Market is 22 December 2022, and new shares are expected to be booked into the respective custodian/VP account on 29 December 2022.
EEVIA HEALTH PLC: FLAGGING NOTIFICATION OF CHANGE OF HOLDINGS BY CEO
2022-12-05 08:24
Stein Ulve, the CEO of Eevia Health Plc, ("Eevia" or "The Company"), subscribed for 489 996 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed. Stein Ulve had 1 907 500 subscription rights, but he subscribed for 489 996 shares. Consequently, he was diluted under the flagging threshold of 10%.
EEVIA HEALTH PLC: FLAGGING NOTIFICATION OF NEW SHAREHOLDING
2022-12-05 08:20
Eevia Health Plc ("the Company" or "Eevia") has become aware that Marizoe Actives S.L. from Madrid, Spain has subscribed for 1 517 459 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed, leading to a new total of shares of 30 349 371. Marizoe Actives S.L. had no shares before the issue and with the subscription, Marizoe has 5.01% of the new outstanding shares.
Eevia Health Plc received small initial sales order for Feno-Sambucus™ from Australia
2022-12-01 13:41
Eevia Health ("Eevia" or "The Company") received a start order for the Feno-Sambucus™ worth SEK 110 000 from its Australian distributor Ingredient Plus. The order is a new start order for an Australian brand owner.
Eevia Health Plc receives a 445 KSEK / 41 KEUR sales order for a Bilberry extract product
2022-11-30 09:51
Eevia Health Plc's ("Eevia" or "The Company") has received a 41 KEUR sales order for Bilberry extract from its distributor in France Natural Ingredients.
Eevia Health Plc
Webbplats:
eeviahealth.com/investors/
Kortnamn: EEVIA
Marknadsplats: Spotlight stock market
Senaste rapporten:
Interim report Q3 2022
Nästa evenemang:
2023-02-24 Bokslutskommuniké 2022
Kurs
Kurs:
Marknadsvärde: